Oracle 2012 Annual Report Download - page 82

our reported cash and cash equivalents balances in U.S. Dollars for fiscal 2012, 2011 and 2010 was a (decrease)
increase of $(471) million, $600 million and $(107) million, respectively. The following table includes estimates
of the U.S. Dollar equivalent of cash, cash equivalents and marketable securities denominated in certain major
foreign currencies as of May 31, 2012:
U.S. Dollar
Equivalent at
(in millions) May 31, 2012
Euro ............................................................................ $ 1,302
Chinese Renminbi ................................................................. 930
Indian Rupee ..................................................................... 814
Japanese Yen ..................................................................... 760
Australian Dollar .................................................................. 712
South African Rand ................................................................ 329
Canadian Dollar .................................................................. 259
British Pound .................................................................... 258
Other foreign currencies ............................................................ 2,002
Total cash, cash equivalents and marketable securities denominated in foreign currencies .... $ 7,366
If overall foreign currency exchange rates in comparison to the U.S. Dollar uniformly weakened by 10%, the
amount of cash, cash equivalents and marketable securities we would report in U.S. Dollars would decrease by
approximately $737 million, assuming constant foreign currency cash, cash equivalent and marketable securities
balances.
Item 8. Financial Statements and Supplementary Data
The response to this item is submitted as a separate section of this Annual Report. See Part IV, Item 15.
Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this Annual Report on Form 10-K, we carried out an evaluation under the
supervision and with the participation of our Disclosure Committee and our management, including the Chief
Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of our
disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(e) and 15d-15(e). Disclosure controls
are procedures that are designed to ensure that information required to be disclosed in our reports filed under the
Securities Exchange Act of 1934, or the Exchange Act, such as this Annual Report on Form 10-K, is recorded,
processed, summarized and reported within the time periods specified by the U.S. Securities and Exchange
Commission. Disclosure controls are also designed to ensure that such information is accumulated and
communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as
appropriate to allow timely decisions regarding required disclosure. Our quarterly evaluation of disclosure
controls includes an evaluation of some components of our internal control over financial reporting. We also
perform a separate annual evaluation of internal control over financial reporting for the purpose of providing the
management report below.
The evaluation of our disclosure controls included a review of their objectives and design, our implementation of
the controls and the effect of the controls on the information generated for use in this Annual Report on Form
10-K. In the course of the controls evaluation, we reviewed data errors or control problems identified and sought
to confirm that appropriate corrective actions, including process improvements, were being undertaken. This type
of evaluation is performed on a quarterly basis so that the conclusions of management, including our Chief
Executive Officer and Chief Financial Officer, concerning the effectiveness of the disclosure controls can be
reported in our periodic reports on Form 10-Q and Form 10-K. Many of the components of our disclosure
78